Merck Management

Management criteria checks 3/4

Merck's CEO is Rob Davis, appointed in Apr 2021, has a tenure of 4.08 years. total yearly compensation is $23.19M, comprised of 7% salary and 93% bonuses, including company stock and options. directly owns 0.018% of the company’s shares, worth CHF28.59M. The average tenure of the management team and the board of directors is 4.3 years and 5.7 years respectively.

Key information

Rob Davis

Chief executive officer

US$23.2m

Total compensation

CEO salary percentage	7.00%
CEO tenure	4.1yrs
CEO ownership	0.02%
Management average tenure	4.3yrs
Board average tenure	5.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rob Davis's remuneration changed compared to Merck's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2025	n/a	n/a	US$17b
Dec 31 2024	US$23m	US$2m	US$17b
Sep 30 2024	n/a	n/a	US$12b
Jun 30 2024	n/a	n/a	US$14b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b

Compensation vs Market: Rob's total compensation ($USD23.19M) is above average for companies of similar size in the Swiss market ($USD5.05M).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.

CEO

Rob Davis (57 yo)

4.1yrs

Tenure

US$23,186,065

Compensation

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Robert Davis	Chairman	4.1yrs	US$23.19m	0.018% CHF 28.6m
Caroline Litchfield	Executive VP & CFO	4.1yrs	US$7.51m	0.0030% CHF 4.8m
Betty Larson	Executive VP & Chief Human Resources Officer	1.1yrs	US$11.26m	0.00025% CHF 404.5k
Richard DeLuca	Executive VP & President of Merck Animal Health	13.7yrs	US$9.10m	0.0073% CHF 11.7m
Dean Li	Executive VP & President of Merck Research Laboratories	7.5yrs	US$10.09m	0.0032% CHF 5.2m
Dalton Smart	Senior VP of Finance	1.4yrs	no data	0.00038% CHF 614.8k
David Williams	Executive VP and Chief Information & Digital Officer	no data	no data	0.00096% CHF 1.6m
Peter Dannenbaum	Vice President of Investor Relations	5.8yrs	no data	no data
Jennifer Zachary	Executive VP & General Counsel	7.1yrs	US$5.90m	0.0022% CHF 3.6m
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	3.8yrs	no data	0.00028% CHF 453.0k
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	15.5yrs	US$6.24m	0.0074% CHF 11.9m
Johannes Oosthuizen	Senior VP & President Merck U.S. Human Health	4.3yrs	no data	0.0012% CHF 2.0m

4.3yrs

Average Tenure

56yo

Average Age

Experienced Management: 010683053's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Davis	Chairman	3.8yrs	US$23.19m	0.018% CHF 28.6m
Pamela Craig	Independent Director	9.7yrs	US$403.75k	0.000070% CHF 113.3k
Patricia Russo	Independent Director	29.7yrs	US$363.75k	0.00052% CHF 841.4k
Thomas Glocer	Independent Lead Director	17.5yrs	US$436.25k	0.00020% CHF 323.6k
Risa Lavizzo-Mourey	Independent Director	5yrs	US$361.00k	0.000040% CHF 64.7k
Douglas Baker	Independent Director	3yrs	US$350.00k	0.00064% CHF 1.0m
Inge Thulin	Independent Director	7.2yrs	US$340.00k	0.00012% CHF 194.2k
Stephen Mayo	Independent Director	4.2yrs	US$350.00k	0% CHF 0
Kathy Warden	Independent Director	5.2yrs	US$350.00k	0.000020% CHF 32.4k
Christine Seidman	Independent Director	5.2yrs	US$375.00k	0% CHF 0
Paul Rothman	Independent Director	9.7yrs	US$413.75k	0% CHF 0
Mary Coe	Independent Director	6.2yrs	US$340.00k	0% CHF 0

5.7yrs

Average Tenure

65.5yo

Average Age

Experienced Board: 010683053's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/20 09:46
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Merck & Co., Inc. is covered by 56 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Fabrizio Spagna	Axia Financial Research
Charles Butler	Barclays

Merck Management

Management criteria checks 3/4

Key information

Recent management updates

Merck & Co., Inc., Annual General Meeting, May 27, 2025

Independent Director recently bought CHF1.2m worth of stock

Merck & Co., Inc. Appoints Surendralal L. Karsanbha to its Board of Directors, Effective January 1, 2025

Recent updates

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival in Patients with Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

Research on Novel Treatment Approaches and Scientific Advances from Merck's Broad and Differentiated Oncology Portfolio and Pipeline to Be Presented at ASCO 2025

Dawn Health and Merck Launch Next-Generation Digital Ecosystem for Growth Disorders

Merck Announces Results from the Phase 3 KEYNOTE-689 Trial Evaluating KEYTRUDA

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Merck & Co., Inc., Annual General Meeting, May 27, 2025

Merck Announces First Presentation of Results from the Phase 3 Zenith Trial Evaluating Winrevair™

Merck & Co., Inc.'s Investigational Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Demonstrates Noninferior Pharmaceuticaletics Compared to Intravenous (IV) KEYTRUDA®? (Pembrolizumab) in Pivotal 3475A-D77 Trial

European Commission Approves Merck's Capvaxive®? (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Merck Data At Acc.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease

Merck Announces Positive Data from Phase 3 Trials That Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir Maintained HIV-1 Viral Suppression At Week 48

Upcoming dividend of US$0.81 per share

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Merck Receives First European Commission Approval for Two Indications

Health Canada Approves Merck's KEYTRUDA® (Pembrolizumab) for the Treatment of Adult Patients with Respirable Non-Small Cell Lung Cancer

Independent Director recently bought CHF1.2m worth of stock

Merck Announces Phase 3 Waveline-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Full year 2024 earnings released: EPS: US$6.74 (vs US$0.14 in FY 2023)

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2025

Third quarter dividend of US$0.81 announced

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis

Merck Announces Second-Quarter 2025 Dividend, Payable on April 7, 2025

FDA Grants Priority Review to Merck's Application for WELIREG (belzutifan) for the Treatment of Patients with Advanced Pheochromocytoma and Paraganglioma (PPGL)

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

Merck’s GARDASIL® Receives Expanded Approval for Males in China

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

Merck & Co., Inc. Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab

Merck Receives Positive EU CHMP Opinion for WELIREG®? (belzutifan) as Treatment for Adult Patients with Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients with Advanced Renal Cell Carcinoma

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer

Merck & Co., Inc. Announces First Presentation of Data from the Phase 2 Waveline-007 Trial Evaluating Zilovertamab Vedotin

Merck & Co., Inc. Announces Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIOTM (Molnupiravir) for the Treatment of Covid-19 in High-Risk Adults

Merck's Sacituzumab Tirumotecan Granted FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck Announces Pivotal Phase 3 Zenith Trial Evaluating Winrevair Met Primary Endpoint At Interim Analysis

Third quarter dividend of US$0.81 announced

Merck & Co., Inc. Appoints Surendralal L. Karsanbha to its Board of Directors, Effective January 1, 2025

Merck & Co., Inc.'s WELIREG (Belzutifan) Approves in China for the Treatment of Adult Patients with Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints

Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: US$1.24 (vs US$1.87 in 3Q 2023)

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

Miller Law LLC and Motley Rice LLC Announce a Proposed Settlement in re Zetia (Ezetimibe) Antitrust Litigation

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Prometheus Biosciences, Inc. (NasdaqGS:RXDX) from a group of shareholders.

U.S. FDA Approves New Indication for Merck's PREVYMIS®? (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

Merck and Canadian Cancer Trials Group Announces Results from the Phase 3 CCTG IND.227/KeyNOTE-483 Trial Evaluating KEYTRUDA

Astrazeneca and MSD's Lynparza (Olaparib) Approves in the US for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Merck Declares Quarterly Dividend on Common Stock for the Third Quarter of 2023, Payable on July 10, 2023

U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk

Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint from Phase 3 Propel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium

Merck Announces Phase 3 NRG-GY018 Trial Evaluating Keytrudav